The mortality associated with candidaemia in the UK continues to be high: our own unpublished data, collected from five centres in the UK during 2008, show a mortality of 40%, similar to that found in earlier studies. 4 This is despite the advent of new antifungal agents and the publication of management standards and guidelines. These documents, published by the British Society for Medical Mycology (BSMM) 5 and the Infectious Diseases Society of America (IDSA), 6 between them recommend choice, dose, and duration of antifungal therapy for candidaemia, and other management strategies such as removal of central venous catheters (CVC) and ophthalmological review for all candidaemic patients. Epidemiological studies have consistently identified intensive care unit (ICU) patients as a high-risk group for Candida bloodstream infections, with 28-47% of episodes occurring in these patients. 3 4 7 8 In the UK, the incidence of candidaemia in ICUs is 1.26 cases per 1000 occupied bed-days 7 or 0.74 per 100 admissions. 8 Despite the importance and frequency of these infections, there are no UK-based studies documenting their usual management. Therefore, we conducted a national survey on the ICU management of Candida infections in the UK. The aims were to obtain information on local expertise and policies, selection of antifungal agents, and attitudes to and practice regarding empirical therapy and the management of patients with proven candidaemia, including adherence to published guidelines. A summary of the main results has been published in abstract form. 9 
Methods
The West of Scotland Research Ethics Service confirmed, on the basis of the nature of the study, that formal ethical review was not required. An electronic questionnaire was designed using SurveyMonkey TM (www.surveymonkey.com) 
Results
Seventy-two responses were received from the 236 surveys sent, giving an overall response rate of 30.5%. The response rate was 54.2% (13/24) in Scotland and 27.8% (59/212) in the rest of the UK. Six of the 72 responses (8.3%) were incomplete; hence, the denominator varies in the observations below.
General information
There is a clinician with a special interest in fungal infections in 20% of units (14/70 
Regarding empirical treatment of infections
Antifungal agents are used empirically in 85.9% of units (61/71). The remaining questions on empirical treatment were shown only to these 61 respondents. Fluconazole was the most commonly used empirical antifungal agent ( Table 2 ). The three free-text answers regarding the choice of the antifungal agent stated the use of anidulafungin, combination of liposomal amphotericin B and posaconazole, and any of fluconazole, caspofungin, or micafungin. Empirical treatment would be considered for any patient in 35.1% of units (20/57), whereas 64.9% (37/57) would consider this only for patients in certain high-risk groups. The definition of a high-risk group varied amongst these 37 respondents (Table 3 ). The groups most commonly suggested include patients with gastrointestinal conditions, immunocompromise, liver failure, or a combination of factors (examples cited included fever, total parenteral nutrition, broad-spectrum antibiotics, and prolonged ICU stay). The majority of respondents (76.4%, 42/55) believe empirical therapy to be beneficial. Table 4 shows responses to the question 'Which of the following is likely to prompt empirical treatment in your unit?'. Many of the suggested factors would prompt empirical 
Regarding treatment of proven candidaemia
Fluconazole is the most commonly used agent for therapy of proven candidaemia (Table 2) . One free-text answer stated that anidulafungin is used and others that the agent used is dependent on microbiological advice, patient group, or consultant preference. Of those who respond that fluconazole is not a first-choice agent, 77% (21/27) would change therapy to fluconazole if the species were subsequently identified as Candida albicans. Only one unit frequently uses combination antifungal agents for therapy. The duration of antifungal therapy is 7 days in 3% of units (2/66), 14 days in 47% (31/66), 21 days in 6.1% (4/66), and at least 3 weeks in 1.5% (1/66). Some units do not give therapy for a specified number of days, but base the duration on clinical response (22.7%, 15/66) or microbiological advice (10.6%, 7/66). Other free-text responses usually stated that the duration of therapy is variable depending on some combination of patient and clinical factors. CVC are removed within 48 h of documentation of candidaemia always in 35.4% (23/65), frequently in 38.5% (25/65), infrequently in 21.5% (14/65), and never in 4.6% (3/65) of units. Ophthalmology review is arranged always in 4.5% of units (3/66), frequently in 10.6% (7/66), infrequently in 34.8% (23/66), and never in 50% (33/66).
Discussion
Our results show that the management of fungal infections is relatively consistent among responding units. Close liaison with microbiologists is common, but some of our data suggest that recent developments in the field have yet to impact on current management.
Over 80% of responding units use empirical antifungal therapy and this is generally perceived to be beneficial. Its use is often reserved for groups of patients considered to be high risk, or individuals with a combination of clinical risk factors. The IDSA recommends considering empirical antifungal therapy for critically ill patients with clinical risk factors for invasive candidiasis and no other known cause of fever, 6 but note that there is little evidence to support this approach. The sole randomized controlled trial of empirical antifungal therapy in ICU patients found no benefit of using fluconazole vs placebo, 10 with successful composite outcome demonstrated in 36% and 38% of each group, respectively. Recognized risk factors in the existing literature are broadly consistent with those cited by survey respondents and include immunosuppression, broad-spectrum antibiotics, acute renal failure, and disorders compromising integrity of the gastrointestinal tract. 11 12 Scoring systems have been developed to identify individual patients who may benefit from empirical therapy, 13 14 but these are not yet fully validated. Although definitive diagnosis of invasive Candida infection is notoriously difficult, 15 there is a risk that the widespread use of antifungal agents empirically may select for resistant organisms. We believe that in the light of the current data, the use of empirical therapy may often not be justified and should be used with caution. For both proven candidaemia and empirical therapy, the IDSA recommends using echinocandins (e.g. caspofungin) first-line for those who are moderately or severely ill, with intention to switch to fluconazole if appropriate after species identification. 6 Among survey respondents, fluconazole is the most commonly used antifungal agent. Although fluconazole is cheap, well-tolerated, and effective against many Candida species, some non-albicans species may be inadequately treated. Candida glabrata causes 15-18% of Candida infections in ICU patients 16 -18 and often displays some resistance to fluconazole, but is sensitive to echinocandins. Echinocandins, unlike fluconazole, are fungicidal and are active against biofilms. 19 The apparent reluctance to use echinocandins first-line is in keeping with ICU practice elsewhere in Europe 16 and may reflect concern regarding cost. However, inadequate treatment of candidiasis correlates with greater cost per patient 20 and higher mortality. 21 If fluconazole is chosen, the high doses recommended by the IDSA 6 (800 mg loading dose, 400 mg daily) should ideally be used. Both the IDSA and the BSMM recommend removal of CVC within 48 h of identification of candidaemia. 5 6 Published audits, including but not confined to intensive care, have found that this target is achieved in 79-84% of patients. 4 22 Our lower figure of 74% might reflect awareness of this recommendation, but it is recognized that in unstable patients, the risks of CVC removal may outweigh the potential benefits. Moreover, the evidence that their retention increases mortality 5 6 remains controversial, since patients with CVC are likely to be more unwell and predisposed to higher mortality. A recent literature review 23 found only one study, demonstrating definite benefit from early CVC removal. 
